|
|
Tandem Diabetes Care Inc (NASDAQ: TNDM) |
|
Price: $16.8500
$0.04 
0.238%
|
| Day's High:
| $17.0049991607666
| Week Perf:
| -11.83 %
|
| Day's Low: |
$ 16.57 |
30 Day Perf: |
-25.84 % |
| Volume (M): |
252,629 |
52 Wk High: |
$ 29.65 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$18.80 |
| Open: |
$16.66 |
52 Wk Low: |
$11.46 |
|
|
| Market Capitalization (Millions $) |
1,163 |
| Shares
Outstanding (Millions) |
69 |
| Employees |
2,500 |
| Revenues (TTM) (Millions $) |
1,037 |
| Net Income (TTM) (Millions $) |
-63 |
| Cash Flow (TTM) (Millions $) |
126 |
| Capital Exp. (TTM) (Millions $) |
27 |
Business Description
Tandem Diabetes Care Inc is a medical device company that is focused on developing and commercializing innovative products for individuals with diabetes. Based in San Diego, California, the company was founded in 2006 and went public in 2013.
Tandem Diabetes Care is primarily known for its insulin pump products, which are small, wearable devices that deliver insulin to people with diabetes. The company's flagship product is the t:slim X2 insulin pump, which was first launched in 2016. This pump uses a touchscreen interface and Bluetooth connectivity to provide patients with real-time data about their insulin delivery and glucose levels. The t:slim X2 also includes software updates that can be downloaded remotely, allowing patients to keep their device up-to-date with the latest features and improvements.
Tandem Diabetes Care has invested heavily in research and development, with a focus on creating products that are easier to use, more accurate, and more effective. The company has also made efforts to improve customer support and education, with a dedicated team of clinical specialists available to help patients learn how to use their devices and manage their diabetes.
In addition to its insulin pump products, Tandem Diabetes Care also offers a range of accessories and supplies, including infusion sets, cartridges, and other items that are needed to use the pump. The company's products are sold in the United States and internationally, with a network of distributors and other partners around the world.
Overall, Tandem Diabetes Care is a leading player in the diabetes care market, with a focus on innovation and customer satisfaction. As the prevalence of diabetes continues to grow globally, the company is well-positioned to serve the needs of patients and healthcare providers, and to continue developing new and improved products in the years ahead.
Company Address: 12400 High Bluff Drive San Diego, 92130 CA
Company Phone Number: 366-6900 Stock Exchange / Ticker: NASDAQ TNDM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Mon, Nov 24 2025 9:02 PM UTC
As we approach the closing months of 2025, Tandem Diabetes Care, Inc. (NASDAQ: TNDM) finds itself under not only the scrutiny of market analysts but also legal examination regarding its business practices. The Rosen Law Firm, a prominent global advocate for investor rights, has initiated inquiries into the company following allegations that it may have provided materially mi...
|
| Business Update
Published Mon, Nov 10 2025 3:19 PM UTC
Tandem Diabetes Secures FDA Approval for Mobile App: A New Era in Insulin Delivery Technology In a significant advancement for diabetes management, Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a pioneering company in the field of insulin delivery and diabetes technology, has announced the U.S. Food and Drug Administration s (FDA) clearance of the Android version of its Tandem ...
|
| Business Update
Published Wed, Oct 29 2025 3:11 PM UTC
In the ever-evolving landscape of diabetes management, Tandem Diabetes Care, Inc. (NASDAQ: TNDM) continues to forge forward with transformative innovations that are set to redefine patient experiences and outcomes. Based in San Diego, Tandem Diabetes Care is a leader in insulin delivery and diabetes technology, with groundbreaking advancements that cater to the nuanced needs...
|
| Business Update
Published Tue, Jan 7 2025 5:32 PM UTC
In a significant move to enhance diabetes management technologies, Tandem Diabetes Care, Inc. has entered a multi-year research collaboration with the University of Virginia Center for Diabetes Technology. The partnership aims to leverage UVA s pioneering advancements in closed-loop insulin delivery systems, which could revolutionize care for individuals living with diabetes...
|
| Business Update
Published Tue, Aug 20 2024 5:35 AM UTC
San Diego Tandem Diabetes Care, Inc. has announced the release of an updated version of its Apple iOS t:connect mobile app, designed specifically for users of the t:slim X2 insulin pump. Scheduled to be available on August 20, 2024, the app update, version 2.8.2, aims to correct battery depletion issues that were highlighted in a nationwide recall issued in March 2024. Us...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.93 $ |
| Revenues (TTM) |
15.03 $
|
| Cash Flow (TTM) |
1.82 $ |
| Cash |
6.61 $
|
| Book Value |
1.89 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
414,921 |
| Net
Income per Employee (TTM) |
-25,326 |
| Receivable Turnover Ratio (TTM) |
6.98 |
| Inventory Turnover Ratio (TTM) |
3.46 |
| Asset Turnover Ratio (TTM) |
1.02 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.93 $
|
| Revenues (TTM) |
15.03 $ |
| Cash Flow (TTM) |
1.82 $ |
| Cash |
6.61 $
|
| Book Value |
1.89 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 133.62 % |
of total Revenue |
| Non-US |
|
63.5 % |
of total Revenue |
| Pump |
|
88.42 % |
of total Revenue |
| Supplies and other |
|
108.7 % |
of total Revenue |
| |
On February 21 2024 the Tandem Diabetes Care Inc provided following guidance
insulin pump, in select international markets. Completed the acquisition of TypeZero Technologies, Inc., enhancing Tandem's automated insulin delivery technology.
Revenue for the quarter ended December 31, 2023, was $200 million, representing a 15% increase compared to the same period in 2022. Gross margin for the quarter was 55%, while operating expenses were $80 million.
For the full year 2023, Tandem reported total revenue of $750 million, a 20% increase from 2022. The company also achieved a gross margin of 56% for the year, with operating expenses totaling $300 million.
Looking ahead to 2024, Tandem Diabetes Care expects continued growth, with projected revenue of $1 billion. The co...
|
|
|
0.4% 